These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 25701315)

  • 1. A novel dengue virus serotype-2 nanovaccine induces robust humoral and cell-mediated immunity in mice.
    Hunsawong T; Sunintaboon P; Warit S; Thaisomboonsuk B; Jarman RG; Yoon IK; Ubol S; Fernandez S
    Vaccine; 2015 Mar; 33(14):1702-10. PubMed ID: 25701315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenic Properties of a BCG Adjuvanted Chitosan Nanoparticle-Based Dengue Vaccine in Human Dendritic Cells.
    Hunsawong T; Sunintaboon P; Warit S; Thaisomboonsuk B; Jarman RG; Yoon IK; Ubol S; Fernandez S
    PLoS Negl Trop Dis; 2015 Sep; 9(9):e0003958. PubMed ID: 26394138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses.
    Wollner CJ; Richner M; Hassert MA; Pinto AK; Brien JD; Richner JM
    J Virol; 2021 May; 95(12):. PubMed ID: 33762420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys.
    Gil L; Izquierdo A; Lazo L; Valdés I; Ambala P; Ochola L; Marcos E; Suzarte E; Kariuki T; Guzmán G; Guillén G; Hermida L
    Virology; 2014 May; 456-457():70-6. PubMed ID: 24889226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses.
    Li S; Peng L; Zhao W; Zhong H; Zhang F; Yan Z; Cao H
    Vaccine; 2011 May; 29(20):3695-702. PubMed ID: 21419774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice.
    Gil L; López C; Lazo L; Valdés I; Marcos E; Alonso R; Gambe A; Martín J; Romero Y; Guzmán MG; Guillén G; Hermida L
    Int Immunol; 2009 Oct; 21(10):1175-83. PubMed ID: 19692540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole inactivated dengue virus-loaded trimethyl chitosan nanoparticle-based vaccine: immunogenic properties in
    Jearanaiwitayakul T; Sunintaboon P; Chawengkittikul R; Limthongkul J; Midoeng P; Chaisuwirat P; Warit S; Ubol S
    Hum Vaccin Immunother; 2021 Aug; 17(8):2793-2807. PubMed ID: 33861177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of tetravalent and conserved synthetic peptides vaccines derived from Dengue virus Envelope domain I and II.
    Rocha RP; Livonesi MC; Fumagalli MJ; Rodrigues NF; da Costa LC; Dos Santos MC; de Oliveira Rocha ES; Kroon EG; Malaquias LC; Coelho LF
    Virus Res; 2014 Aug; 188():122-7. PubMed ID: 24768848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus Type 1.
    Friberg H; Martinez LJ; Lin L; Blaylock JM; De La Barrera RA; Rothman AL; Putnak JR; Eckels KH; Thomas SJ; Jarman RG; Currier JR
    mSphere; 2020 Jan; 5(1):. PubMed ID: 31969476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a recombinant, chimeric tetravalent dengue vaccine candidate.
    Osorio JE; Partidos CD; Wallace D; Stinchcomb DT
    Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage.
    Keelapang P; Nitatpattana N; Suphatrakul A; Punyahathaikul S; Sriburi R; Pulmanausahakul R; Pichyangkul S; Malasit P; Yoksan S; Sittisombut N
    Vaccine; 2013 Oct; 31(44):5134-40. PubMed ID: 23973247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective Protection Induced by a Monovalent DNA Vaccine against Dengue Virus (DV) Serotype 1 and a Bivalent DNA Vaccine against DV1 and DV2 in Mice.
    Zheng X; Chen H; Wang R; Fan D; Feng K; Gao N; An J
    Front Cell Infect Microbiol; 2017; 7():175. PubMed ID: 28553618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.
    Liu G; Song L; Beasley DW; Putnak R; Parent J; Misczak J; Li H; Reiserova L; Liu X; Tian H; Liu W; Labonte D; Duan L; Kim Y; Travalent L; Wigington D; Weaver B; Tussey L
    Clin Vaccine Immunol; 2015 May; 22(5):516-25. PubMed ID: 25761459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys.
    Suzarte E; Gil L; Valdés I; Marcos E; Lazo L; Izquierdo A; García A; López L; Álvarez M; Pérez Y; Castro J; Romero Y; Guzmán MG; Guillén G; Hermida L
    Int Immunol; 2015 Aug; 27(8):367-79. PubMed ID: 25795768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
    Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
    Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An intact signal peptide on dengue virus E protein enhances immunogenicity for CD8(+) T cells and antibody when expressed from modified vaccinia Ankara.
    Quinan BR; Flesch IE; Pinho TM; Coelho FM; Tscharke DC; da Fonseca FG
    Vaccine; 2014 May; 32(25):2972-9. PubMed ID: 24726244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice.
    Chiang CY; Liu SJ; Hsieh CH; Chen MY; Tsai JP; Liu HH; Chen IH; Chong P; Leng CH; Chen HW
    Vaccine; 2016 Feb; 34(8):1054-61. PubMed ID: 26776472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
    Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
    Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-response study in mice of a tetravalent vaccine candidate composed of domain III-capsid proteins from dengue viruses.
    Valdés I; Marcos E; Suzarte E; Pérez Y; Brown E; Lazo L; Cobas K; Yaugel M; Rodríguez Y; Gil L; Guillén G; Hermida L
    Arch Virol; 2017 Aug; 162(8):2247-2256. PubMed ID: 28393307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.